Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| MGTX | PRESS-RELEASE | neutral | 5/10 | MeiraGTx reported Q2 2026 GAAP net income of $160.7M ($1.71 diluted EPS) vs a net loss of $38.8M ($-0.48) a year ago, dr | Aug 13, 2026 |
| GRCE | 8-K | neutral | 5/10 | Grace Therapeutics reported Q1 2027 results with a net loss of $15.8M ($0.91/share), significantly wider than the $3.4M | Aug 13, 2026 |
| GRCE | PRESS-RELEASE | mixed | 5/10 | Grace Therapeutics reported a net loss of $15.8M for Q1 FY2027 (June 30, 2026), driven by a $13.5M impairment of IPR&D f | Aug 13, 2026 |
| ARTL | PRESS-RELEASE | neutral | 4/10 | Artelo Biosciences reported Q2 2026 net loss of $2.4M ($0.89/share) vs $3.2M in Q2 2025, with R&D expenses halved to $0. | Aug 13, 2026 |
| MGTX | 8-K | neutral | 5/10 | MeiraGTx reported Q2 2026 GAAP net income of $160.7M ($1.71 diluted EPS) vs a net loss of $38.8M ($-0.48) a year ago, dr | Aug 13, 2026 |
| ASND | PRESS-RELEASE | bullish | 7/10 | Ascendis Pharma reported Q2 2026 product revenue of €315M (+105% YoY), driven by YORVIPATH (€252M) and SKYTROFA (€55M), | Aug 13, 2026 |
| CLRB | PRESS-RELEASE | neutral | 4/10 | Cellectar Biosciences reported Q2 2026 net loss of $6.9M ($0.57/share) vs $5.4M ($3.39/share) in Q2 2025, with R&D spend | Aug 13, 2026 |
| ABEO | PRESS-RELEASE | mixed | 6/10 | Abeona reported Q2 2026 net ZEVASKYN revenue of $11.4M, up 31% QoQ, with five patients treated. However, EPS of -$0.35 m | Aug 13, 2026 |
| CRMD | PRESS-RELEASE | neutral | 5/10 | No summary provided | Aug 13, 2026 |
| NGEN | PRESS-RELEASE | neutral | 5/10 | NervGen Pharma reported Q2 2026 EPS of -$0.06, beating consensus of -$0.07 by 9.8%, but the company remains pre-revenue | Aug 13, 2026 |
| FTLF | PRESS-RELEASE | mixed | 5/10 | FitLife Brands reported Q2 2026 revenue of $26.5M (+65% YoY, beating $26.0M consensus) but diluted EPS of $0.20 missed t | Aug 13, 2026 |
| CABA | PRESS-RELEASE | neutral | 4/10 | Cabaletta Bio reported Q2 2026 EPS of -$0.34, beating consensus of -$0.37 by 8.1%, with no revenue. The company highligh | Aug 13, 2026 |
| INKT | PRESS-RELEASE | mixed | 6/10 | MiNK Therapeutics reported Q2 2026 net loss of $3.1M ($0.62/share), improving from $4.2M ($1.06/share) in Q2 2025, with | Aug 13, 2026 |
| PTHS | 8-K | bearish | 6/10 | Pelthos Therapeutics reported Q2 2026 revenue of $15.4M (up 45% QoQ) driven by strong Zelsuvmi prescription growth, but | Aug 13, 2026 |
| PULM | PRESS-RELEASE | bearish | 6/10 | Pulmatrix reported Q2 2026 financial results with minimal revenue, a net loss of $1.0M, and a cash burn that reduced its | Aug 13, 2026 |
| CLRB | 8-K | neutral | 4/10 | Cellectar Biosciences reported Q2 2026 net loss of $6.9M ($0.57/share) vs $5.4M ($3.39/share) in Q2 2025, with R&D spend | Aug 13, 2026 |
| INDP | 8-K | neutral | 5/10 | Indaptus Therapeutics reported Q2 2026 results with no active clinical programs, having discontinued its Decoy20 study. | Aug 13, 2026 |
| ABEO | 8-K | neutral | 5/10 | Abeona reported Q2 2026 net product revenue of $11.4M, up 31% QoQ from $8.7M in Q1 2026, driven by five patient treatmen | Aug 13, 2026 |
| CABA | 8-K | neutral | 4/10 | Cabaletta Bio reported Q2 2026 net loss of $-0.34 per share, which is in line with the consensus estimate of $-0.37 (a 8 | Aug 13, 2026 |
| CRMD | 8-K | neutral | 5/10 | CorMedix reported Q2 2026 consolidated revenue of $101.9M and net income of $26.0M ($0.33 basic EPS), compared to $39.7M | Aug 13, 2026 |
| KPTI | 8-K | bearish | 8/10 | Karyopharm reported Q2 2026 total revenue of $33.4M, down 12% YoY from $37.9M, driven by a $5.6M decline in license and | Aug 13, 2026 |
| INKT | 8-K | mixed | 6/10 | MiNK Therapeutics reported Q2 2026 net loss of $3.1M ($0.62/share), improving from $4.2M ($1.06/share) in Q2 2025, with | Aug 13, 2026 |
| PYXS | 8-K | mixed | 5/10 | Pyxis Oncology reported Q2 2026 results with a net loss of $25.3M ($0.40/share), wider than the prior year's $18.4M loss | Aug 13, 2026 |
| ATHE | 6-K | bullish | 5/10 | Alterity Therapeutics announced the USPTO granted a new composition-of-matter patent for ATH434, its lead clinical asset | Aug 13, 2026 |
| IFRX | EFFECT | bearish | 5/10 | InflaRx N.V.'s shelf registration statement (F-3, File No. 333-298039) became effective on August 12, 2026, allowing the | Aug 13, 2026 |
| CAMP | EFFECT | neutral | 3/10 | Camp4 Therapeutics Corp's S-3 shelf registration statement (File No. 333-298067) was declared effective by the SEC on Au | Aug 13, 2026 |
| CRIS | EFFECT | bearish | 6/10 | Curis Inc.'s S-1 registration statement (File No. 333-298203) was declared effective by the SEC on August 12, 2026, unde | Aug 13, 2026 |
| SLBT | EFFECT | neutral | 4/10 | SL Science Holding Ltd's F-1 registration statement (File No. 333-297881) became effective on August 12, 2026, covering | Aug 13, 2026 |
| DMRA | EFFECT | neutral | 3/10 | Damora Therapeutics' shelf registration (File No. 333-292175) became effective on August 12, 2026, under the Securities | Aug 13, 2026 |
| SGMOQ | 8-K | mixed | 7/10 | Sangamo Therapeutics, in Chapter 11, completed a Section 363 asset auction, selecting winning bids from PTC Therapeutics | Aug 13, 2026 |